PREDICTIVE ASSESSMENT OF MALIGNANCY RISK IN OVARIAN CYSTIC LESIONS BASED ON MORPHOLOGICAL AND MOLECULAR MARKERS

Authors

  • Yakubbekova S.S. Department of Oncology, Andijan State Medical Institute Andijan, Uzbekistan Author

Keywords:

ovarian cystic lesions, ovarian cancer, malignant transformation, malignancy risk, morphology, immunohistochemistry, molecular biomarkers, p53, Ki-67, BRCA1/2.

Abstract

Ovarian cystic lesions represent a heterogeneous group of pathological conditions ranging from benign functional and neoplastic processes to borderline tumors and invasive ovarian carcinomas. Differential diagnosis and assessment of malignant potential remain important challenges in gynecologic oncology. Conventional imaging, serum tumor markers, and histopathological examination provide essential diagnostic information; however, individual parameters may have insufficient specificity for accurate risk stratification. The integration of morphological, immunohistochemical, and molecular characteristics may improve the identification of ovarian lesions with increased malignant potential. Particular attention is currently focused on morphological indicators of epithelial proliferation and invasion, proliferative activity assessed by Ki-67, abnormal p53 expression, and molecular alterations involving TP53, BRCA1/2, KRAS, BRAF, PIK3CA, PTEN, and ARID1A. An integrated multiparametric approach may improve differential diagnosis, prognostic assessment, and individualized clinical decision-making.

References

1.WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.

2.Kurman RJ, Shih IM. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. Am J Pathol. 2016;186(4):733–747.

3.Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615.

4.Prat J, D'Angelo E, Espinosa I. Ovarian carcinomas: at least five different diseases with distinct histological features and molecular genetics. Hum Pathol. 2018;80:11–27.

5.Bowtell DD, Böhm S, Ahmed AA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15(11):668–679.

6.Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. Lancet. 2019;393(10177):1240–1253.

7.Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.

8.Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952.

Downloads

Published

2026-09-17